News | March 19, 2013

Screening for BNP, Targeted Care Reduce Heart Failure in At-Risk Patients

Study shows simple blood test may help patients with risks for heart disease

 

March 19, 2013 — Alere Inc. announced the results of research presented at the American College of Cardiology’s 62nd Annual Scientific Session, which showed that a simple screening and management program can be effective in preventing heart failure for at-risk patients.

The five-year STOP-HF study enrolled asymptomatic patients over 40 years of age with risk factors for heart failure and randomized them into intervention and control groups. Patients in the intervention group were screened for blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart is functioning, using the Alere Triage Meter and, if necessary, received specialized care. Control-group patients continued to receive standard care from their physicians. Researchers found that a significantly lower number of patients in the intervention group than in the control group met the primary endpoint of new onset heart failure requiring hospitalization or left ventricular dysfunction (5.3 vs. 8.7 percent, p = 0.01).

“The results of this study indicated that use of BNP in the community may facilitate prevention strategies aimed at reducing heart failure, left ventricular dysfunction and cardiovascular events,” said Kenneth McDonald, M.D., director of the Heart Failure Unit at St. Vincent’s University Hospital in Dublin and one of the authors on the STOP-HF study. “Our study shows that a simple blood test screening, followed by targeted care of people at heightened risk of heart failure, can result in a dramatic reduction in cardiovascular events. This is good news, since heart failure has become a major public health problem and middle-aged adults today have a 20 to 30 percent lifetime risk of developing heart failure.”

Nearly 6 million Americans have heart failure, a condition in which heart function has deteriorated as a result of various forms of damage, including prior heart attack, chronic high blood pressure, diabetes and obesity. Elevated BNP levels can indicate established heart failure, and healthcare providers use patients’ BNP levels to determine the severity. BNP levels can also, as shown by the STOP-HF study, be used to indicate risk of heart failure and the possible need for more focused intervention.

The STOP-HF study recruited 1,374 patients from 39 family practices. The patients in the intervention arm were screened at least annually for cardiovascular risks and blood levels of BNP. Two in five (41.6 percent) patients in the intervention group showed elevated BNP levels at some point during the study. These patients received an echocardiogram and continued care under both their physicians and a specialist cardiology service. In addition to showing lower rates of the primary endpoint, intervention patients also had lower rates of emergency hospitalization for major cardiovascular events (22.3 vs. 40.4 per 1,000 patient years, p<0.001).

“While we have made great strides in the management of heart failure, outlook for these patients remains poor with reduced longevity and quality of life. The STOP-HF project provides the first example of how a structured screening and intervention strategy can prevent heart failure,” McDonald said.

Most other studies on heart failure have focused on treatment of the established syndrome, and researchers hope the results of this study will encourage healthcare providers to look at prevention while also implementing simple, low-cost screening systems for their at-risk patients.

Researchers recommend that their study population be followed over time to see whether intervention benefits persist, and that the study be repeated in other healthcare systems. They hope to evaluate other potential screening tests to identify additional patients at risk for heart failure.

The STOP-HF study was funded by the Health Services Executive and the Health Research Board of the Irish government, the European Commission Framework Programme 7 Media Project, and the Heartbeat Trust, an independent charity focused on heart failure prevention. The Heartbeat Trust has received unrestricted educational and research grants from Alere, Pfizer, A. Menarini, Roche, Takeda, Abbott, Servier and Merck.

For more information: www.alere.com

Related Content

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init